EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Predicting Poor Efficacy of Cabozantinib in Advanced Renal Cell Carcinoma by Exploratory Metabolic Pathway Analysis and In Vitro Verification

Takanari Sakai, Yoshihide Kawasaki iD, Izumi Sakamoto, Eiji Hishinuma iD, Naomi Matsukawa, Daigo Chiba, Tomonori Sato iD, Kento Morozumi iD, Masamitsu Maekawa iD, Nariyasu Mano, Akihiro Ito

Cancer Medicine · 2026

DOI: 10.1002/cam4.72145 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Takanari Sakai und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Anilides, Pyridines, Kidney Neoplasms. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research (KAKENHI), Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cabozantinib (CABO) is currently an essential drug for first‐line and sequential therapy in the treatment of advanced renal cell carcinoma (RCC). Predicting its therapeutic efficacy will enable efficient drug selection and improve the prognosis of patients. We conducted an exploratory study to predict the effects of CABO using metabolite analysis with clinical and in vitro samples.

Methods

Patients diagnosed with RCC at our hospital between September 2011 and August 2023 who were pathologically diagnosed with clear cell RCC and subsequently received systemic therapy for disease progression or recurrence were included. Patient background, treatment course, and prognosis were retrospectively investigated. Patients were divided into CABO responders and poor responders based on survival analysis. Comprehensive metabolite analysis of serum samples before CABO administration was performed using a non‐targeted analysis system (Orbitrap) with a mass spectrometer. The significance of metabolic pathways related to the poor response of CABO analysis was evaluated by establishing CABO‐resistant renal cancer cell lines and conducting in vitro quantitative analysis.

Results

A total of 19 analyzable cases were identified during the study period, and seven pathways (methylhistamine metabolism, caffeine metabolism, beta‐alanine metabolism, histidine metabolism, glycine and serine metabolism, tryptophan metabolism, and purine metabolism) and five metabolites (methylhistidine, kynurenic acid, xanthine, 7‐methylxanthine, and L‐2‐amino‐3‐oxobutanoic acid) related to the poor efficacy of CABO were identified in a two‐group comparison. Quantitative metabolite analysis of CABO‐resistant cell lines established from three different renal cancer cell lines (786‐O, ACHN, and Caki‐1) confirmed the identified pathways and metabolites in relation to CABO resistance.

Conclusion

We identified key metabolites and associated metabolic pathways that may serve as predictive biomarkers for suboptimal cabozantinib efficacy in patients with advanced RCC. While further validation in independent cohorts is warranted, our findings underscore the potential of metabolomic profiling to refine therapeutic selection and improve clinical outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellAnilidesPyridinesKidney NeoplasmsMetabolic Networks and PathwaysProtein Kinase InhibitorsHumansFemaleMalePrognosisCell Line, TumorRetrospective StudiesMiddle AgedAgedDrug Resistance, NeoplasmMetabolomicsTreatment Outcome

Stichwörter der Autor:innen

cabozantinibdrug resistanceefficacy predictionmetabolic pathwaysrenal cell carcinoma

Substanzen

cabozantinibAnilidesPyridinesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Advanced Research Center for Innovations in Next-Generation Medicine and Tohoku Medical Megabank Organization, Sendai, Japan.
  • Department of Urology, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
  • Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan.

ORCID-Profile: Yoshihide Kawasaki, Eiji Hishinuma, Tomonori Sato, Kento Morozumi, Masamitsu Maekawa

Förderung

  • Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research (KAKENHI)
  • Japan Society for the Promotion of Science

Zitieren

APA

Sakai, T., Kawasaki, Y., Sakamoto, I., Hishinuma, E., Matsukawa, N., Chiba, D., Sato, T., Morozumi, K., Maekawa, M., Mano, N., & Ito, A. (2026). Predicting Poor Efficacy of Cabozantinib in Advanced Renal Cell Carcinoma by Exploratory Metabolic Pathway Analysis and In Vitro Verification. Cancer Medicine. https://doi.org/10.1002/cam4.72145

Vancouver

Sakai T, Kawasaki Y, Sakamoto I, Hishinuma E, Matsukawa N, Chiba D, et al. Predicting Poor Efficacy of Cabozantinib in Advanced Renal Cell Carcinoma by Exploratory Metabolic Pathway Analysis and In Vitro Verification. Cancer Medicine. 2026. doi:10.1002/cam4.72145

BibTeX
@article{Sakai2026,
  author = {Sakai, Takanari and Kawasaki, Yoshihide and Sakamoto, Izumi and Hishinuma, Eiji and Matsukawa, Naomi and Chiba, Daigo and Sato, Tomonori and Morozumi, Kento and Maekawa, Masamitsu and Mano, Nariyasu and Ito, Akihiro},
  title = {Predicting Poor Efficacy of Cabozantinib in Advanced Renal Cell Carcinoma by Exploratory Metabolic Pathway Analysis and In Vitro Verification},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.72145}
}
Kostenlos starten →